Macrophage migration inhibitory factor (MIF), C-reactive protein (CRP) and C3a serum levels following coronary artery bypass graft surgery (CABG)
Critical Care2001Vol. 5(Suppl 3), pp. P21–P21
HTF Mendonça F°, HCC Faria Neto, Patrı́cia T. Bozza, Rômulo Dias Novaes, Fernando A. Bozza, RV Gomes, LA Campos, MA Fernandes, PM Nogueira, HF Dohmann
Abstract
Objectives: In the treatment of acute myocardial infarction (MI), the time delay to achieve reperfusion of the infarction-related artery has been linked to survival rates. Primary or direct angioplasty has been found to be an excellent means of achieving reperfusion in acute ST-elevation MI compared to thrombolytic therapy in randomized trials. However, no mortality benefit of primary angioplasty over thrombolysis was observed in several registries, in which delays in performing primary angioplasty were longer. Our objectives were to evaluate the door-to-balloon time (DBT) in our institution and investigate its relationship with clinical and prognostic variables.
Related Papers
- → Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels(2013)30 cited
- → Serum macrophage migration inhibitory factor (MIF) in the intercritical phase of hereditary periodic fevers and its relationship with theMIF‐173G/C polymorphism(2007)6 cited
- → Inhibitory Effort of the N-terminal GST on the Tautomerase Activity of Macrophage Migration Inhibitory Factor(2005)1 cited
- MIF水平及MIF-173G／C多态性与恩施地区土家族银屑病关联性研究(2015)
- → P106 Active macrophage migration inhibitory factor (MIF) is a previously unrecognized isoform of MIF and a potential new biomarker for inflammatory bowel diseases(2013)